

CITATION REPORT

List of articles citing

Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel

DOI: 10.1002/hep.22555
Hepatology, 2008, 48, 1779-90.

Source: <https://exaly.com/paper-pdf/43430229/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo. 2008 , 49, 908-15		17
104	The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. 2009 , 106, 12712-6		126
103	Plugging the holes in hepatitis C virus antiviral therapy. 2009 , 106, 12567-8		18
102	Suppression of a pro-apoptotic K ⁺ channel as a mechanism for hepatitis C virus persistence. 2009 , 106, 15903-8		56
101	Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. 2009 , 83, 7970-81		60
100	Lipid droplets and hepatitis C virus infection. 2009 , 1791, 552-9		71
99	HCV NS2/3 protease: a future antiviral drug target?. 2009 , 4, 463-472		1
98	Ion channels as antiviral targets. 2010 , 25, 267-80		10
97	Development of novel antiviral therapies for hepatitis C virus. 2010 , 25, 246-66		22
96	New antiviral therapies for chronic hepatitis C. 2010 , 4, 548-61		89
95	A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. 2010 , 55, 2629-35		7
94	A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. 2010 , 86, 144-53		73
93	Cell permeabilization by poliovirus 2B viroporin triggers bystander permeabilization in neighbouring cells through a mechanism involving gap junctions. 2010 , 12, 1144-57		12
92	NMR structure and ion channel activity of the p7 protein from hepatitis C virus. 2010 , 285, 31446-61		113
91	Hepatitis C virus: assembly and release of virus particles. 2010 , 285, 22733-9		84
90	Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles. 2010 , 91, 362-72		81
89	Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. 2010 , 6, e1001233		144

88	Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. 2010 , 6, e1001087		135
87	Last stop before exit - hepatitis C assembly and release as antiviral drug targets. 2010 , 2, 1782-803		4
86	Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. 2010 , 2, 2078-95		37
85	Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon- α 2011 , 140, 1032-42		120
84	Viral proteins function as ion channels. 2011 , 1808, 510-5		100
83	Mixing the right hepatitis C inhibitor cocktail. 2011 , 17, 34-46		31
82	Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target. 2011 , 31, 606-17		14
81	Therapeutic applications of iminosugars: current perspectives and future opportunities. 2011 , 50, 135-76		64
80	Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. <i>Hepatology</i> , 2011 , 54, 79-90	11.2	59
79	Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. 2011 , 85, 2891-906		61
78	Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. 2011 , 85, 8913-28		73
77	Development and validation of a high-throughput screening assay for the hepatitis C virus p7 viroporin. 2011 , 16, 363-9		15
76	Hepatitis C virus-induced autophagy is independent of the unfolded protein response. 2012 , 86, 10724-32		48
75	High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. 2012 , 86, 5341-51		73
74	Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. 2012 , 86, 2143-52		12
73	Direct-acting and host-targeting HCV inhibitors: current and future directions. 2012 , 2, 588-98		29
72	Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naïve hepatitis C genotype 1 patients. 2012 , 16, e748-52		3
71	Viroporins: structure and biological functions. 2012 , 10, 563-74		268

70	Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection. 2012 , 423, 30-7	12
69	Computational modeling of the p7 monomer from HCV and its interaction with small molecule drugs. 2013 , 2, 324	10
68	Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function. 2013 , 94, 2236-2248	25
67	Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7. 2013 , 94, 2221-2235	16
66	Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 2013 , 19, 837-49	425
65	Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. 2013 , 100, 636-9	10
64	The p7 protein of hepatitis C virus is degraded via the proteasome-dependent pathway. 2013 , 176, 211-5	10
63	Evidence suggesting that HCV p7 protects E2 glycoprotein from premature degradation during virus production. 2013 , 176, 199-210	13
62	Hepatitis C virus-specific directly acting antiviral drugs. 2013 , 369, 289-320	24
61	The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. 2013 , 113, 3516-604	378
60	CHAPTER 9:Virus-coded Ion Channels as Antiviral Targets. 2013 , 295-362	
59	Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. 2013 , 87, 1664-78	38
58	Unusual architecture of the p7 channel from hepatitis C virus. 2013 , 498, 521-5	207
57	Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. <i>Hepatology</i> , 2014 , 59, 408-22	11.2 49
56	"Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?. 2014 , 6, 1893-907	8
55	Current and future targets of antiviral therapy in the hepatitis C virus life cycle. 2014 , 9, 947-965	3
54	Docking assay of small molecule antivirals to p7 of HCV. 2014 , 53PB, 308-317	19
53	The minimalist architectures of viroporins and their therapeutic implications. 2014 , 1838, 1058-67	30

52	On the history of hepatitis C virus cell culture systems. 2014 , 57, 1627-42	67
51	The elusive function of the hepatitis C virus p7 protein. 2014 , 462-463, 377-87	27
50	Ion-dynamics in hepatitis C virus p7 helical transmembrane domains--a molecular dynamics simulation study. 2014 , 192, 33-40	17
49	The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences. 2014 , 448, 117-24	12
48	Human adenovirus spread, rainfalls, and the occurrence of gastroenteritis cases in a Brazilian basin. 2015 , 187, 720	8
47	Structural and Functional Properties of the Hepatitis C Virus p7 Viroporin. 2015 , 7, 4461-81	33
46	Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. 2015 , 7, 5746-66	33
45	Relevance of Viroporin Ion Channel Activity on Viral Replication and Pathogenesis. 2015 , 7, 3552-73	48
44	Viral Membrane Channels: Role and Function in the Virus Life Cycle. 2015 , 7, 3261-84	23
43	Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. 2015 , 10, e0121099	32
42	Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds. 2015 , 10, e0126510	13
41	Investigation of Molecular Mechanism of JC virus Viroporin Activity. 2015 , 65, 135-44	
40	Viroporins: structure, function and potential as antiviral targets. 2015 , 96, 2000-2027	61
39	Transverse relaxation dispersion of the p7 membrane channel from hepatitis C virus reveals conformational breathing. 2015 , 61, 369-78	17
38	Strain-specific antiviral activity of iminosugars against human influenza A viruses. 2015 , 70, 136-52	27
37	Targeting the Channel Activity of Viroporins. 2016 , 104, 307-355	11
36	Hepatitis C virus: The role of N-glycosylation sites of viral genotype 1b proteins for formation of viral particles in insect and mammalian cells. 2016 , 7, 98-105	2
35	A functional NMR for membrane proteins: dynamics, ligand binding, and allosteric modulation. 2016 , 25, 959-73	13

34	Structural basis of interaction between the hepatitis C virus p7 channel and its blocker hexamethylene amiloride. 2016 , 7, 300-304	7
33	Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. 2016 , 110, 2419-2429	18
32	Functional characterization of p7 viroporin from hepatitis C virus produced in a cell-free expression system. 2016 , 118, 83-91	6
31	The p7 viroporin of the hepatitis C virus contributes to liver inflammation by stimulating production of Interleukin-1. 2017 , 1863, 712-720	20
30	Peptide carbocyclic derivatives as inhibitors of the viroporin function of RNA-containing viruses. 2017 , 43, 517-525	2
29	The Unusual Transmembrane Partition of the Hexameric Channel of the Hepatitis C Virus. 2018 , 26, 627-634.e416	
28	Understanding the inhibitory mechanism of BIT225 drug against p7 viroporin using computational study. 2018 , 233, 47-54	10
27	Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7. 2018 , 12, 1019-1031	4
26	Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. 2018 , 158, 214-235	14
25	Enhancing Hepatitis C virus pseudoparticles infectivity through p7NS2 cellular expression. 2019 , 274, 113714	5
24	Critical Effect of the Detergent:Protein Ratio on the Formation of the Hepatitis C Virus p7 Channel. 2019 , 58, 3834-3837	5
23	Cyclopeptides design as blockers against HCV p7 channel in silico. 2019 , 45, 1419-1425	0
22	Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. 2019 , 11,	36
21	Iminosugars: A host-targeted approach to combat Flaviviridae infections. 2020 , 184, 104881	11
20	Inhibitor Development against p7 Channel in Hepatitis C Virus. 2021 , 26,	2
19	Inhibitors of the Small Membrane (M) Protein Viroporin Prevent Zika Virus Infection.	1
18	Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels. 2021 , 102,	3
17	Structural and Functional Properties of Viral Membrane Proteins. 2018 , 147-181	3

16	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. 2017 , 553-627	0
15	The subcellular localization of the hepatitis C virus non-structural protein NS2 is regulated by an ion channel-independent function of the p7 protein. 2011 , 92, 819-30	37
14	NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system. 2014 , 95, 2427-2441	1
13	Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy.	1
12	In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure. 2014 , 9, e93613	7
11	The N-terminal Helical Region of the Hepatitis C Virus p7 Ion Channel Protein Is Critical for Infectious Virus Production. 2015 , 11, e1005297	14
10	Is There a Link Between the Pathogenic Human Coronavirus Envelope Protein and Immunopathology? A Review of the Literature. 2020 , 11, 2086	28
9	Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy. 2020 , 9,	3
8	HCV Drug Resistance. 2017 , 579-609	
7	Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease. 2021 , 13,	1
6	Repurposing Novel Antagonists to p7 Viroporin of HCV Using in silico Approach. 2022 , 19,	
5	Image_1.JPEG. 2020 ,	
4	Table_1.docx. 2020 ,	
3	Identification of a novel class of cyclic penta-peptides against hepatitis C virus as p7 channel blockers. 2022 , 20, 5902-5910	0
2	Synthesis of novel azasugar-containing 2-RC-Me 9-deaza nucleosides as potential anti-hepatitis C virus agents. 1-11	0
1	Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites. 2023 , 13,	0